PMID- 17295769
OWN - NLM
STAT- MEDLINE
DCOM- 20070709
LR  - 20131121
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 22
IP  - 3
DP  - 2007 Mar
TI  - Effects of thalidomide in experimental models of post-endoscopic retrograde 
      cholangiopancreatography pancreatitis.
PG  - 371-6
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) plays a central role in the 
      pathogenesis of acute pancreatitis and related systemic complications. The 
      authors hypothesized that it may also play an important role in the development 
      of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). The 
      aim of the study was to evaluate the effectiveness of thalidomide, an 
      immunomodulator that exerts an inhibitory action on TNF-alpha by enhancing mRNA 
      degradation, in reducing post-ERCP pancreatitis in a rat model. METHODS: A total 
      of 200 mg/kg thalidomide was given intragastric once a day (total 8 days) before 
      the experimental models of post-ERCP pancreatitis were established. After 24 h, 
      histology and edema of pancreas, serum amylase, and TNF-alpha mRNA in the 
      pancreatic tissue were evaluated. RESULTS: Intraductal contrast infusion caused 
      increases in serum amylase, edema, histological grade, and TNF-alpha mRNA of 
      pancreas. The prophylactic use of thalidomide significantly reduced serum 
      amylase, pancreatic edema and the histologic grade of pancreatitis accompanied by 
      a decrease in mRNA expression of TNF-alpha in the pancreatic tissue. CONCLUSIONS: 
      Prophylactic intragastric administration of thalidomide provides a protective 
      effect in post-ERCP pancreatitis. The mechanism of the protective effects of 
      thalidomide seems to be the reduction of expression of TNF-alpha mRNA in 
      pancreatic tissue.
FAU - Xiong, Guang-Su
AU  - Xiong GS
AD  - Department of Gastroenterology, Renji Hospital, Shanghai Jiaotong University, 
      Shanghai Institute of Digestive Disease, Shanghai, China.
FAU - Wu, Shu-Ming
AU  - Wu SM
FAU - Wang, Zhen-Hua
AU  - Wang ZH
FAU - Mo, Jian-Zhong
AU  - Mo JZ
FAU - Xiao, Shu-Dong
AU  - Xiao SD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Immunosuppressive Agents)
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
MH  - Animals
MH  - Cholangiopancreatography, Endoscopic Retrograde/*adverse effects
MH  - Disease Models, Animal
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Pancreatitis/*etiology/*prevention & control
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thalidomide/*therapeutic use
EDAT- 2007/02/14 09:00
MHDA- 2007/07/10 09:00
CRDT- 2007/02/14 09:00
PHST- 2007/02/14 09:00 [pubmed]
PHST- 2007/07/10 09:00 [medline]
PHST- 2007/02/14 09:00 [entrez]
AID - JGH4552 [pii]
AID - 10.1111/j.1440-1746.2006.04552.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2007 Mar;22(3):371-6. doi: 
      10.1111/j.1440-1746.2006.04552.x.